Sector: MedicalRigel Pharmaceuticals, Inc. (NASDAQ: RIGL)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 169 |
Technical : | 110 |
Performance : | 232 |
Overall: | 194 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 214 |
Technical : | 306 |
Performance : | 285 |
Overall: | 300 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 208 |
Technical : | 295 |
Performance : | 292 |
Overall: | 299 |
Number of Stocks: | 306 |
Headlines
- Rigel Announces Third Quarter 2009 Financial Results
Nov 03, 2009 07:01 AM | RIGL
- Rigel Announces Presentations at Two Investor Conferences
Oct 28, 2009 07:31 AM | RIGL
- RidgewaterEquity.com Free Fundamental Sector & Market Research on SGEN, PLUG, RIGL, PAET, RPRX and PLAB
Oct 22, 2009 06:31 AM | PAET, PLUG, RIGL, SGEN
- Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
Sep 17, 2009 09:19 AM | RIGL
- Rigel Announces Proposed Offering of 6,000,000 Shares of Common Stock
Sep 16, 2009 04:00 PM | RIGL
- BioMedReports FDA Calendar: 19 Hot Summer Trades
Jun 17, 2009 08:18 AM | ACUR, AEZS, ALTH, AMAG, AUXL, DDSS
- Rigel And Seattle Genetics -The Delicate Art Of Expectation Management
Feb 10, 2009 12:15 AM | ALTH, CELG, CVTX, PFE, RIGL, SGEN
- Biotech Portfolio Updates - Rigel Is Still On Track, Pfizer May Have Found Its Next Blockbuster
Jan 09, 2009 10:11 AM | ARQL, BBI, BMY, EXEL, PFE, RIGL
- Immunogen and Exelixis Defy the Myth of Recession
Dec 20, 2008 09:14 PM | ARQL, BMY, DNA, EXEL, GSK, IMGN
- Rigel Pharmaceuticals– Crisis Or Opportunity?
Nov 10, 2008 09:57 AM | ABT, AGN, AMGN, CVTX, GILD, INCY
- Rigel Announces Second Quarter 2009 Financial Results
Aug 04, 2009 07:51 AM | RIGL
- The Rosen Law Firm, P.A. Encourages Rigel Pharmaceuticals, Inc. Shareholders to Evaluate Their Legal Rights
Jul 31, 2009 11:24 AM | RIGL
- R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Jul 23, 2009 06:01 PM | RIGL
- Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis
Jul 23, 2009 12:02 PM | RIGL
- Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Jul 08, 2009 09:00 PM | RIGL
- Rigel to Present at Jefferies Healthcare Conference
Jun 10, 2009 07:31 AM | RIGL
- Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers
Jun 01, 2009 07:31 AM | RIGL
- Rigel to Present at JMP Securities Research Conference
May 13, 2009 07:31 AM | RIGL
- Rigel Announces First Quarter 2009 Financial Results
May 05, 2009 07:54 AM | RIGL
- Rigel to Present at Citi's Biotech Day
Mar 27, 2009 07:30 AM | RIGL
- Form 4 RIGEL PHARMACEUTICALS For: May 29 Filed by: LYONS GARY A (10K)
May 29, 2009 09:46 PM
- Form 4 RIGEL PHARMACEUTICALS For: May 29 Filed by: MOOS WALTER H (10K)
May 29, 2009 09:17 PM
- Form 4 RIGEL PHARMACEUTICALS For: May 29 Filed by: RENTON HOLLINGS (10K)
May 29, 2009 09:04 PM
- Form 4 RINGROSE PETER S For: May 29 (10K)
May 29, 2009 08:53 PM
- Form 4 RIGEL PHARMACEUTICALS For: May 29 Filed by: SHERWIN STEPHEN A (10K)
May 29, 2009 08:53 PM
- Form 4 RIGEL PHARMACEUTICALS For: May 29 Filed by: Goodwin Bradford S (10K)
May 29, 2009 08:20 PM
- Form 4 RIGEL PHARMACEUTICALS For: May 29 Filed by: DELEAGE JEAN (10K)
May 29, 2009 08:17 PM
- Form 4 RIGEL PHARMACEUTICALS For: Mar 30 Filed by: Maynard Ryan D (10K)
Mar 31, 2009 08:03 PM
- Form 4 RIGEL PHARMACEUTICALS For: Mar 30 Filed by: VANCE DOLLY (10K)
Mar 31, 2009 07:58 PM
- Form 4 RIGEL PHARMACEUTICALS For: Mar 30 Filed by: RODRIGUEZ RAUL R (10K)
Mar 31, 2009 07:51 PM
Analyst Ratings
Share Performance
|
Period
|
RIGL
|
Compare to S&P
|
| YTD |
-6.50 %
|
-22.77 %
|
| 4 Weeks |
4.18 %
|
3.63 %
|
| 12 Weeks |
-10.53 %
|
-16.04 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 13.58 %
|
|
EPS Growth in Last Year: 32.04 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
